NAMS - NewAmsterdam Pharma Company Debt to Book Capitalization Ratio

Graphic logo of NewAmsterdam Pharma Company (NAMS)

NewAmsterdam Pharma (NAMS) is developing the innovative Obicetrapib pill to combat high cholesterol, replacing costly injections by blocking the CETP protein. However, fierce competition from industry behemoths and the risk of trial failures are creating significant pressure. This daily price action, shown below, is recorded at 0.00. Laboratory production capacities comply with global standards, and all clinical trials are conducted strictly according to regulations.

NAMS (NewAmsterdam Pharma Corp) Debt to Book Value history from 06/21/2023 to 10/28/2026

NewAmsterdam Pharma Company (NAMS) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Price NewAmsterdam Pharma|NAMS - Analyst Consensus Forecast
- market capitalization data:
Market Value NewAmsterdam Pharma Corp|NAMS - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share NewAmsterdam Pharma|NAMS - Company Net Assets|Market Capitalization to Book Value Ratio newamsterdampharma.com|NAMS - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio NewAmsterdam Pharma|NAMS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity NewAmsterdam Pharma N.V.|NAMS - Company Total Debt|Debts to Book Capitalization NewAmsterdam Pharma Corp|NAMS - Long-Term Debt|Company Current Liabilities NewAmsterdam Pharma
Fundamental company analysis:NewAmsterdam Pharma - NAMS
Core merchandise of NewAmsterdam Pharma N.V.

The dynamic financial leverage trend on the balance sheet reflects the ability of NewAmsterdam Pharma (NAMS) to maintain its capital base prior to entering the premium cardiology drug market. This indicator compares total liabilities with balance sheet equity in real-time, allowing investors to assess the degree of debt load and default risks between quarterly reports to protect capital from volatility.

Competitors of NewAmsterdam Pharma (NAMS)

Debts to Book Capitalization ASND (Ascendis Pharma A/S)|madrigalpharma.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Corcept Therapeutics Incorporated (CORT)|RYTM: Debt to Net Assets Ratio|AKRO (Akero Therapeutics Inc) - Debt to Book Capitalization Ratio|Metsera Therapeutics (MTSR) - Debt to Book Value|MLTX (MoonLake Immunotherapeutics) - Debts to Book Capitalization|Debts to Book Capitalization crinetics.com (CRNX)|Soleno Therapeutics, Inc. (SLNO) - Debt to Book Value|Debt to Net Assets Ratio FOLD (Amicus Therapeutics Inc)|89bio Corp - Debt to Book Capitalization Ratio|Debt to Book Value Agios Corp AGIO|GPCR (Structure Therapeutics) - Debts to Book Capitalization|mimedx.com (MDXG) - Debts to Book Value|RZLT - Debt to Book Value|Lexicon Pharmaceuticals Inc (LXRX) - Debt to Book Capital|MBX (MBX Bio) - Debts to Book Capitalization|Debts to Book Capitalization Altimmune Pharma|Debts to Book Capitalization Aardvark Therapeutics Inc (AARD)|Debt to Book Capitalization Ratio SGMT (sagimet.com)|BIOA: Debt to Book Capitalization Ratio|Biomea Fusion Inc - Debts to Book Value|QNCX - Debt to Book Capitalization Ratio|GUTS - Debt to Book Capitalization Ratio|vtvtherapeutics.com - Debts to Book Capitalization|ATPC (Agape ATP) - Debts to Net Assets|PLUR: Debt to Book Capitalization Ratio|Debts to Net Assets SYBX|Debt to Book Capitalization Ratio LPCN (Lipocine Corp)|Debt to Book Value MTNB (matinasbiopharma.com)|SPRB - Debt to Book Capitalization Ratio|Debt to Book Value Ratio galecto.com GLTO|CTCX (Carmell) - Debts to Book Capitalization|Lumos Pharma Inc (LUMO) - Debts to Book Value|ONVO (Organovo Holdings Inc) - Debt to Book Value|Radius Pharmaceuticals (RDUS) - Debt to Book Value